Blockade of the PI3K/AKT/mTOR pathway has shown encouraging pre-clinical results, indicating a potential strategy for SCLC treatment through a combination of clinically approved PI3K and mTOR inhibitors [128]. Here, MTOR is linked to small cell lung carcinoma.